Treatment of lupus nephritis: a meta-analysis of clinical trials (Q40906582)

24 September 2017

0 references

Treatment of lupus nephritis: a meta-analysis of clinical trials (English)

1 reference

24 September 2017

1 reference

Bansal VK

1

1 reference

PubMed ID

9016889

24 September 2017

Beto JA

series ordinal

2

1 reference

24 September 2017

1 February 1997

1 reference

American Journal of Kidney Diseases

24 September 2017

1 reference

24 September 2017

29

1 reference

24 September 2017

2

1 reference

24 September 2017

193-199

1 reference

Immunosuppressive drug therapy in lupus nephritis

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Evidence for the Superiority of Immunosuppressive Drugs and Prednisone over Prednisone Alone in Lupus Nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Treatment of Lupus Nephritis with Prednisone and Combined Prednisone and Azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Cyclophosphamide in lupus nephritis: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Azathioprine in the treatment of systemic lupus erythematosus. A controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Improvement of renal function with selective thromboxane antagonism in lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

A meta-analysis of methods to prevent venous thromboembolism following total hip replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Some statistical methods for combining experimental results

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

An assessment of clinically useful measures of the consequences of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990029-9

7 January 2021

10.1016/S0272-6386(97)90029-9

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9016889